Logo image
Antisense oligonucleotides as potential therapeutics for Type 2 Diabetes
Journal article   Peer reviewed

Antisense oligonucleotides as potential therapeutics for Type 2 Diabetes

S. Chen, N. Sbuh and R.N. Veedu
Nucleic Acid Therapeutics, Vol.31(1), pp.39-47
2020
url
Free to Read *No subscription requiredView

Abstract

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from inefficient signaling and insufficient production of insulin. Conventional management of T2D has largely relied on small molecule-based oral hypoglycemic medicines, which do not halt the progression of the disease due to limited efficacy and induce adverse effects as well. To this end, antisense oligonucleotide has attracted immense attention in developing antidiabetic agents because of their ability to downregulate the expression of disease-causing genes at the RNA and protein level. To date, seven antisense agents have been approved by the United States Food and Drug Administration for therapies of a variety of human maladies, including genetic disorders. Herein, we provide a comprehensive review of antisense molecules developed for suppressing the causative genes believed to be responsible for insulin resistance and hyperglycemia toward preventing and treating T2D.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
2 Chemistry
2.170 Nucleic Acids Chemistry
2.170.988 Oligonucleotide Modifications
Web Of Science research areas
Biochemistry & Molecular Biology
Chemistry, Medicinal
Medicine, Research & Experimental
ESI research areas
Biology & Biochemistry
Logo image